Clinical trials: Immune-Mediated Hepatitis
Immune-Mediated Hepatitis
Checkpoint Inhibitor-induced Liver Injury
In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and…
- Trial name
- ChILI (NCT04476563)
- Testing
- Obtaining biological samples
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- University of Nottingham
Immune-mediated Hepatitis
Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
Identify specific blood biomarkers for hepatitis induced by immune checkpoint inhibitors in comparison to idiopathic autoimmune hepatitis.
- Trial name
- Pro-CHILI (NCT06470997)
- Testing
- Blood sample collection, Liver biopsy
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Montpellier
Autoimmune Hepatitis
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
VAY736 dose testing; VAY736 efficacy and safety testing.
- Trial name
- AMBER (NCT03217422)
- Testing
- VAY736
- Where
- 28 sites in United States, Argentina and 8 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Immune-Mediated Cholestasis
Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis
The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period.
- Trial name
- CHILURSO (NCT07378761)
- Testing
- UDCA (Ursodeoxycholic acid), Corticosteroids (Reference Treatment)
- Where
- 6 sites in France
- Volunteers
- 94 people
- Sponsor
- University Hospital, Montpellier
Immune-Mediated Hepatitis, Liver Failure
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
This study aims to investigate the efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma.
- Conditions
- Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT05484908
- Testing
- DPMAS+LPE, PE, Comprehensive internal medical treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Immune Related Adverse Events, Immune-Mediated Hepatitis
Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids
This study evaluates the effectiveness of low-dose corticosteroids in managing grade 2-3 immune-related hepatitis in cancer patients treated with immune checkpoint inhibitors.
- Conditions
- Immune Related Adverse Events, Immune-Mediated Hepatitis, Cancer
- Trial name
- MIRA-HEP (NCT07167251)
- Testing
- Low-dose corticosteroids for immune-related hepatitis grade 3, Low-dose corticosteroids for immune-related hepatitis grade 2
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 63 people
- Sponsor
- University Hospital, Basel, Switzerland
Hepatitis C, HIV Infection
Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV
This study will evaluate the accuracy of an experimental test method called nucleic acid amplification technology (NAT) in detecting human immunodeficiency virus (HIV) and hepatitis C virus (HCV).
- Trial name
- NCT00004846
- Testing
- ABC/Gen-Probe/Chiron HIV-1/HCV 001
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Parvovirus B19 Infection
Parvovirus B19 Infection in Hereditary Hemolytic Anemias Patients
Although many studies investigated the prevalence and manifestations of HPV-B19 infection in patients with sickle cell anemia (SCA), thalassemia, and hereditary spherocytosis (HS) separately, there is limited information about…
- Trial name
- NCT04822090
- Testing
- Supportive treatment with or without red cell transfusion/intravenous immune globulin (IVIG)
- Where
- Egypt
- Volunteers
- 244 people
- Sponsor
- Sohag University
Immune-mediated Hepatitis, Immune-related Adverse Event
Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
This phase II study evaluates whether early treatment with mycophenolate mofetil (MMF) plus prednisone improves liver inflammation caused by immune checkpoint inhibitors.
- Trial name
- NCT07663422
- Testing
- Mycophenolate Mofetil plus prednisone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Fox Chase Cancer Center